By ADAM COHEN
The controversy over the 340B Drug Pricing Program is difficult. Nevertheless, past the arguments over rebates, contract pharmacies, and program intent sits an easier actuality that each stakeholder ought to plan round. No matter type 340B takes subsequent, the worth a corporation captures will depend upon its potential to doc and justify each discounted transaction with detailed, defensible knowledge. Most organizations will not be but outfitted to try this.
The stakes are rising, and so is the burden of proof
Coated entities bought roughly $100 billion in outpatient medication by 340B in 2025, in accordance with the Well being Sources and Companies Administration (HRSA), practically double the 2022 complete. Hospitals and clinics use these financial savings to fund uncompensated care, rural entry, and companies for underserved sufferers. Producers argue this system has outgrown its unique intent and level to the duplicate reductions and diversion that HRSA audits have recognized. Contract pharmacies are caught between producer restrictions, state protections, and the litigation that adopted.
HRSA’s revised rebate pilot, scheduled to start in January 2027, establishes that as an alternative of receiving the low cost on the level of buy, taking part suppliers can pay extra upfront, submit claims knowledge, and obtain the 340B value afterward. Suppliers are proper to fret about money circulate and administrative load ensuing from this shift. Nevertheless, the extra lasting change is the place the burden now sits. Suppliers should show eligibility, transaction by transaction, earlier than they’re made complete.
Whether or not the rebate mannequin expands, stalls in court docket, or offers approach to one thing else, the trajectory is similar. Organizations can be anticipated to point out, with rising precision, why a transaction qualifies and what proof helps that conclusion.
The info exists. Simply not in a single place.
All of it sounds manageable till you attempt it. Substantiating a single 340B transaction might require pharmacy claims, medical claims, affected person and encounter data, payer data, and wholesaler and buying knowledge, in addition to contract-pharmacy data. A few of it’s structured and lives in reviews, exports, invoices, and different paperwork. Different items of data are managed by third events. And, as anybody with expertise in healthcare knowledge is aware of, the identical knowledge ingredient might look radically totally different relying on which system produced it.
The American Hospital Affiliation made precisely this level in its feedback on the rebate proposal, noting that required pharmacy and medical claims data typically resides in separate methods, with different crucial data coming from nonetheless different inner and exterior sources. All this should be extracted, reconciled, and validated earlier than it may be submitted.
This in the end is the crux of the issue. Having knowledge someplace within the enterprise shouldn’t be the identical as having usable knowledge, and usable knowledge shouldn’t be the identical as validated, transaction-level proof that may stand as much as a producer dispute or audit.
Shifting knowledge and successfully utilizing it will not be the identical
For years, the info dialog in healthcare has centered on interoperability. 340B exposes a considerably more durable drawback. Organizations should absorb data from many sources, in a number of codecs, and switch it right into a constant, auditable account of what really occurred. Meaning extracting the related information, normalizing them, reconciling them throughout pharmacy, medical, monetary and buying methods, making use of compliance guidelines, flagging what’s lacking or conflicting, and preserving a transparent path again to the supply.
Automation is important at this quantity. Nevertheless, “largely proper” shouldn’t be ok when the output determines whether or not a reduction is obtained or an audit is survived. The purpose is to not take away folks from the method. It’s to let the overwhelming majority of transactions circulate by reliably, in order that human experience is spent on the exceptions that genuinely require judgment. And since a lot of the proof sits with wholesalers, pharmacies, and payers, this functionality has to work throughout a corporation’s associate ecosystem, not simply inside its personal partitions.
The readiness check
An important query for healthcare executives shouldn’t be whether or not they help or oppose a specific reform. It’s whether or not their group may meet a extra data-intensive commonplace tomorrow. Are you able to determine each system that holds the data wanted to substantiate a 340B transaction? Are you able to pull it collectively with out armies of analysts and spreadsheets, reconcile conflicting data, and hint any submitted knowledge ingredient again to its supply? Are you able to catch exceptions earlier than they change into misplaced reductions or audit findings? And may you do all of this at scale?
Organizations that can’t reply sure have a data-readiness drawback, no matter how the 340B coverage debate ends. The error can be to deal with it as a short lived compliance train, including one other spreadsheet, one other handbook workflow, or one other rent each time the principles change. The higher path is to construct a sturdy knowledge layer between fragmented supply methods and outcomes the group should be capable of show.
Proof is turning into the worth of participation
That functionality is not going to matter just for 340B. Reimbursement, prior authorization, high quality reporting, and value-based preparations are all shifting towards a world through which organizations should show outcomes utilizing data assembled from disparate methods. 340B is just the clearest, highest-dollar instance at present. Stakeholders will preserve debating how this system ought to evolve, and healthcare leaders don’t want to attend for that debate to finish earlier than taking motion. The organizations that defend their 340B financial savings, and the sufferers these financial savings help, would be the ones that begin turning fragmented data into defensible knowledge now, whereas the controversy continues to be ongoing.
Adam Cohen is co-founder of Morph Services.
